Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies
This study systematically assessed and compared temporal changes in genomic biomarker-based eligibility for precision oncology therapies as a function of inferred genetic ancestry derived from DNA sequencing data. Despite the accelerated rate of FDA approvals for precision oncology therapies over the past decade, measurable differences in biomarker-based drug eligibility among patient ancestral groups exist. These differences may exacerbate the systemic disparities in clinical outcomes in patients of African ancestry due to existing deficiencies in their access to cancer care.
Authors
- Debyani Chakravarty (ORCID: https://orcid.org/0000-0001-8629-5732)
- Ritika Kundra (ORCID: https://orcid.org/0000-0001-6723-2859)
- Sarah P. Suehnholz
- Carol L. Brown (ORCID: https://orcid.org/0000-0001-8411-2023)
- Kanika S. Arora (ORCID: https://orcid.org/0000-0001-9537-8708)
- Nikolaus Schultz (ORCID: https://orcid.org/0000-0002-0131-4904)
- Marc Ladanyi (ORCID: https://orcid.org/0000-0001-9055-7213)
- Irina Ostrovnaya (ORCID: https://orcid.org/0000-0003-1783-0070)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Subhiksha Nandakumar (ORCID: https://orcid.org/0000-0003-0258-3484)
- Moriah H. Nissan (ORCID: https://orcid.org/0000-0001-5852-3419)
- Chaitanya Bandlamudi (ORCID: https://orcid.org/0000-0003-1108-4919)
- A. Rose Brannon (ORCID: https://orcid.org/0000-0003-4610-0149)
- Michael F. Berger
- Hongxin Zhang (ORCID: https://orcid.org/0000-0003-2239-5974)
- David B. Solit (ORCID: https://orcid.org/0000-0002-6614-802X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Molecular Oncology (United States) (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1001/jamaoncol.2024.5794
- Citations
- 9
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 8.43